Boyce S, Rupniak N M, Steventon M J, Iversen S D
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
Psychopharmacology (Berl). 1990;102(1):21-7. doi: 10.1007/BF02245739.
Intermittent treatment with L-dopa over a 2-year period induced abnormal involuntary movements in MPTP-treated squirrel monkeys. Dyskinesias included a choreic and dystonic component. Dose-response curves for chorea and dystonia revealed that the same dose of L-dopa (30 mg/kg) induced the highest score for both dyskinesias: however, the severity was much greater for chorea. Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at "end-of-dose", and was occasionally observed spontaneously. Our findings indicate that squirrel monkeys treated with MPTP develop L-dopa-induced dyskinesias which closely resemble those observed in Parkinson's disease. This species provides a valuable animal model to develop improved therapeutic agents.
在两年时间里对用MPTP处理过的松鼠猴进行左旋多巴间歇性治疗，诱发了异常的不自主运动。运动障碍包括舞蹈症和肌张力障碍成分。舞蹈症和肌张力障碍的剂量反应曲线显示，相同剂量的左旋多巴（30毫克/千克）诱发两种运动障碍的得分最高：然而，舞蹈症的严重程度要大得多。舞蹈样动作在药效峰值时总是最为普遍，而肌张力障碍在药效峰值时和“剂量末期”都很明显，并且偶尔会自发出现。我们的研究结果表明，用MPTP处理过的松鼠猴会出现与帕金森病中观察到的非常相似的左旋多巴诱发的运动障碍。这个物种为开发改进的治疗药物提供了一个有价值的动物模型。
